Top Markets
Coin of the day
Dong-A ST Co., Ltd. Dong-A ST Co., Ltd.

Dong-A ST Co., Ltd.

170900
株式のランク #17346
Dong-A ST Co., Ltd. is a global enterprise focused on the research,... Dong-A ST Co., Ltd. is a global enterprise focused on the research, development, production, and commercialization of a broad spectrum of pharmaceutical products and medical devices. The company's diverse portfolio of ethical drugs targets various medical conditions, including tuberculosis (with treatments like Closerin and Terizidone), neutropenia in chemotherapy patients (such as Dulastin and Leucostim), and anemia stemming from chronic renal failure (Eporon). Its robust oncology offerings feature Gemcit for cancers affecting the lung, pancreas, breast, bladder, and ovaries; Mainta for non-small cell lung cancer and malignant pleural mesothelioma; and Monotaxel, indicated for breast, prostate, head, neck, and gastric adenocarcinoma, among others. Additionally, Dong-A ST provides solutions for infertility and anovulation (Gonadopin), growth hormone deficiency and idiopathic short stature (Growtropin II), functional dyspepsia (Motilitone), gastritis (Stillen), diabetes (Suganon), and erectile dysfunction (Zydena). The company also actively participates in pharmaceutical licensing, encompassing both the acquisition and out-licensing of drugs. Its medical device segment includes advanced technological equipment, customized products, and specialized artificial cardiac circuit sets essential for complex open-heart surgeries. Dong-A ST Co., Ltd. was established in 1932 and is headquartered in Seoul, South Korea.
株価
$25.52
時価総額
$246.07M
変化(1日)
-2.25%
変化(1年)
-4.13%
KR
取引 Dong-A ST Co., Ltd. (170900)

カテゴリー

Dong-A ST Co., Ltd.(170900)の配当利回りの履歴
Dong-A ST Co., Ltd.(銘柄コード: 170900)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Dong-A ST Co., Ltd.(170900)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)